# Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis

> **NCT05122559** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Emmanuelle Waubant, MD PhD** · enrollment: 98 (estimated)

## Conditions studied

- Multiple Sclerosis
- Multiple Sclerosis, Primary Progressive
- Multiple Sclerosis, Secondary Progressive

## Interventions

- **DRUG:** N-acetyl cysteine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05122559
- **Lead sponsor:** Emmanuelle Waubant, MD PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-16
- **Primary completion:** 2027-02
- **Final completion:** 2027-02
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2026-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05122559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05122559, "Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT05122559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*